申请人:Cellixbio Private Limited
公开号:US20150141468A1
公开(公告)日:2015-05-21
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used to the treatment of diabetes, lipid peroxidation, hypertriglyceridemia, metabolic disorders, free radical generated due to reactive oxygen and carbonyl groups, ionizing radiation, advanced glycation end products, kidney disease, renal complications and kidney stone disease.
该发明涉及具有化学式I的化合物或其药用可接受的盐,以及其多晶形、溶剂合物、对映体、立体异构体和水合物。包括化合物I的有效量的药物组合物,以及用于治疗或预防代谢紊乱的方法可以制备为口服、颊下、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物也可用于治疗糖尿病、脂质过氧化、高三酰甘油血症、代谢紊乱、由于活性氧和醛基产生的自由基、电离辐射、高级糖基化终产物、肾病、肾脏并发症和肾结石病。